Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part B Drug Use “Substantially” Higher In 2004, CMS Says

Executive Summary

Use of physician-administered drugs under Medicare Part B increased "substantially" in 2004, the Centers for Medicare & Medicaid Services told the Medicare Payment Advisory Commission March 31

You may also be interested in...



Medicare Rx Requires Pharmacies To Mind Their B’s And D’s

Pharmacists will have to keep careful track of prescriptions for some medicines that can be covered by Medicare Part B once the new Part D outpatient drug benefit begins in 2006

Medicare Rx Requires Pharmacies To Mind Their B’s And D’s

Pharmacists will have to keep careful track of prescriptions for some medicines that can be covered by Medicare Part B once the new Part D outpatient drug benefit begins in 2006

J&J Procrit Medicare Reimbursement Will Be 87% Of AWP Under Final Rule

Johnson & Johnson's Procrit will be reimbursed at 87% of average wholesale price under Medicare Part B in 2004, two percentage points higher than most drugs

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel